Moderna: promising results for new Covid vaccine
'We are delighted to announce our fourth infectious disease vaccine program with positive Phase 3 data, validating our robust mRNA platform,' said Stéphane Bancel, President and CEO of Moderna.
mRNA-1283 is an essential component of our combined COVID-19 and influenza vaccine, mRNA-1083, and this milestone gives us confidence in our ability to bring this much-needed vaccine to market', he added.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction